Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
Subtype terms (27)
More specific conditions that are subtypes of Chronic Disease in the MeSH hierarchy.
- Brain Damage, Chronic
- Candidiasis, Chronic Mucocutaneous
1 drug approved
- Chemical and Drug Induced Liver Injury, Chronic
1 drug approved
- Chronic Exertional Compartment Syndrome
3 drugs approved
- Chronic Kidney Disease-Mineral and Bone Disorder
163 drugs (93 approved, 70 experimental)
- Chronic Limb-Threatening Ischemia
73 drugs (27 approved, 46 experimental)
- Chronic Periodontitis
92 drugs (40 approved, 52 experimental)
- Chronic Urticaria
61 drugs (29 approved, 32 experimental)
- Fatigue Syndrome, Chronic
76 drugs (43 approved, 33 experimental)
- Granulomatous Disease, Chronic
52 drugs (30 approved, 22 experimental)
- Hematoma, Subdural, Chronic
19 drugs (18 approved, 1 experimental)
- Hepatitis, Chronic
22 drugs (13 approved, 9 experimental)
- Jaundice, Chronic Idiopathic
- Leukemia, Lymphocytic, Chronic, B-Cell
623 drugs (231 approved, 392 experimental)
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
260 drugs (137 approved, 123 experimental)
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
134 drugs (105 approved, 29 experimental)
- Leukemia, Myelomonocytic, Chronic
237 drugs (130 approved, 107 experimental)
- Leukemia, Neutrophilic, Chronic
37 drugs (32 approved, 5 experimental)
- Multiple Chronic Conditions
2 drugs (1 approved, 1 experimental)
- Multiple Sclerosis, Chronic Progressive
81 drugs (44 approved, 37 experimental)
- Ophthalmoplegia, Chronic Progressive External
1 drug approved
- Pancreatitis, Chronic
48 drugs (34 approved, 14 experimental)
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
39 drugs (22 approved, 17 experimental)
- Post-Infectious Disorders
2 drugs approved
- Pulmonary Disease, Chronic Obstructive
493 drugs (222 approved, 271 experimental)
- Renal Insufficiency, Chronic
472 drugs (259 approved, 213 experimental)
- Wasting Disease, Chronic
14 drugs (3 approved, 11 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (11)
Phase 3 trials (6)
Phase 2 trials (23)
- busulfan
- imatinib
- platelet-rich plasma
- rimabotulinumtoxinB
- cow milk
- ponatinib
- zarnestra
- allogeneic hematopoietic stem cells
- cyclosporine
- mycophenolate
- dasatinib
- allogeneic lymphocytes
- tropisetron
- Anti-thymocyte Globulin (Rabbit)
- autologous mesenchymal stem cells
- fludarabine
- methadone
- sodium chloride
- nilotinib
- mrna-1273
- autologous hematopoietic stem cells
- casirivimab
- imdevimab
Phase 1 trials (4)
Organizations
Organization Involved with Phase 4 Indications (31)
- FLUIDDA nv
- Astellas
- Schering-Plough
- Merck
- Pfizer
- Zambon
- Almirall
- Getz Pharma
- GlaxoSmithKline
- Jordi Gol i Gurina Foundation
- The Netherlands Asthma Foundation
- Medical Research Council
- University of London
- Hamamatsu University
- Karadeniz Technical University
- Radboud University
- University of Dundee
- Aga Khan University
- Capital Medical University
- University of California, San Francisco
- University of Chicago
- Southern Medical University
- British Heart Foundation
- University of Oxford
- ZNA Middelheim
- University of Sao Paulo
- National Health and Medical Research Council, Australia
- Dutch Health Care Insurance Board
- University of Antwerp
- People's Liberation Army of China
- +1 more
Organization Involved with Phase 3 Indications (35)
- Accentia Biopharmaceuticals
- Bristol-Myers Squibb
- MedImmune
- Novartis
- Allergan
- DSM
- Endo Pharmaceuticals
- Intersect ENT
- OptiNose AS
- Oklahoma Medical Research Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute on Aging (NIA)
- University of Illinois
- Maastricht University
- Emory University
- Henan University of Traditional Chinese Medicine
- Hospital Son Llatzer
- Kaiser Permanente
- LifeBridge Health
- Northwestern University
- Queen's University, Belfast
- University of Florida
- Justus Liebig University Giessen
- University of Michigan
- University of Oklahoma
- University of Pisa
- University of Rochester
- University of Bordeaux
- University of California, Los Angeles
- Henan Medical University
- +5 more
Organization Involved with Phase 2 Indications (34)
- Daiichi Sankyo
- ChemGenex Pharmaceuticals
- Celgene
- AstraZeneca
- Asana BioSciences
- FerruMax Pharmaceuticals, Inc.
- Knopp Biosciences
- Naryx Pharma
- Ortho Biotech, Inc.
- National Cancer Institute (NCI)
- National Institute on Drug Abuse (NIDA)
- United States Army
- University of Pennsylvania
- Hospital General Universitario Gregorio Marañon
- McGill University
- Norwegian University of Science and Technology
- Oakland University
- Universidad Complutense de Madrid
- University of South Florida
- University of Toronto
- University of Bern
- Mayo Clinic
- University of Utah
- Icahn School of Medicine at Mount Sinai
- Davita Clinical Research
- Aquinox Pharamceuticals Inc
- University of Lille
- Watson Pharmaceuticals
- Noxxon AG
- University of Texas at Houston
- +4 more
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (16)
- National Institutes of Health (NIH)
- University of Washington
- University of Georgia
- University of Iowa
- University of Reading
- Assiut University
- Chinese University of Hong Kong
- Tel Aviv University
- The University of Hong Kong
- Saskatchewan Pulse Growers
- PepsiCo
- Government of Hong Kong
- The Hong Kong Society of Nephrology
- University of Grenoble
- American Pecan Council
- Espacio Gaspar Clinic